The molecular pathogenesis of head and neck cancer

Cancer Biology and Therapy

Volumn 9, Issue 1, 2010, Pages

  Klein, Jonah D ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Head and neck squamous cell carcinoma; Molecular targeted therapy; Pathogenesis; Tumor microenvironment; Vascular endothelial growth factor receptor

Indexed keywords

ADVEXIN; ALCOHOL; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FORETINIB; GEFITINIB; IMC A 12; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NSC 724772; PANITUMUMAB; SARACATINIB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; STAT3 PROTEIN; STAT3 PROTEIN DECOY; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 880;

BREAST CANCER; CANCER GROWTH; CANCER RISK; CARCINOMA IN SITU; CLINICAL TRIAL; DRUG MECHANISM; DYSPLASIA; HEAD AND NECK CARCINOMA; HUMAN; INVASIVE CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; METASTASIS; PATHOGENESIS; PHENOTYPE; PRECANCER; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TOBACCO; VIRUS INFECTION; DISEASE COURSE; DRINKING BEHAVIOR; FEMALE; GENETICS; HEAD AND NECK TUMOR; MALE; MUTATION; PATHOLOGY; RISK FACTOR; SMOKING; VIROLOGY;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MUTATION; RISK FACTORS; SMOKING; TUMOR VIRUS INFECTIONS;

EID: 85046915740     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.1.10905     Document Type: Review

References (75)

1. Curado M, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Current Opinion in Oncology 2009; 21:194-200.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
3. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head & Neck 2007; 29:779-92.
4. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007; 99:777-89.
5. Chen X, Sturgis EM, Etzel CJ, Wei Q, Li G. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer 2008; 113:3307-14.
6. Ragin CCR, Modugno F, Gollin SM. The Epidemiology and Risk Factors of Head and Neck Cancer: a Focus on Human Papillomavirus. Journal of Dental Research 2007; 86:104-14.
7. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: An evolving treatment paradigm. Cancer 2008; 113:1911-32.
8. Bhuvanesh S. Molecular pathogenesis of head and neck cancers. Journal of Surgical Oncology 2008; 97:634-9.
9. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF, et al. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 2009; 30:416-22.
10. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, et al. Occurrence of p53 Gene Deletions and Human Papilloma Virus Infection in Human Head and Neck Cancer. Cancer Res 1992; 52:4832-6.
11. Hoffmann TK, Sonkoly E, Hauser U, van Lierop A, Whiteside TL, Klussmann JP, et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral oncology 2008; 44:1100-9.
12. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
13. Bolt J, Vo QN, Kim W-J, McWhorter AJ, Thomson J, Hagensee ME, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral oncology 2005; 41:1013-20.
14. ARFin Patients with Severe Oral Epithelial Dysplasia. Cancer Res 2002; 62:5295-300.
15. Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2007; 28:2008-12.
16. Hennessey PT, Westra WH, Califano JA. Human Papillomavirus and Head and Neck Squamous Cell Carcinoma: Recent Evidence and Clinical Implications. Journal of Dental Research 2009; 88:300-6.
17. Chung CH, Gillison ML. Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications. Clinical Cancer Research 2009.
18. Grandis JR, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGFalpha and EGFR in head and neck cancer cell lines. Nat Med 1996; 2:237-40.
19. Kalyankrishna S, Grandis JR. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer. J Clin Oncol 2006; 24:2666-72.
20. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, et al. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research 2006; 12:5064-73.
21. Leeman RJ, Lui VWY, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opinion on Biological Therapy 2006; 6:231-41.
22. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal Growth Factor Receptor-independent Constitutive Activation of STAT3 in Head and Neck Squamous Cell Carcinoma Is Mediated by the Autocrine/Paracrine Stimulation of the Interleukin 6/gp130 Cytokine System. Cancer Res 2003; 63:2948-56.
23. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer and Metastasis Reviews 2003; 22:309-25.
24. Dong G, Chen Z, Li Z-Y, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte Growth Factor/Scatter Factor-induced Activation of MEK and PI3K Signal Pathways Contributes to Expression of Proangiogenic Cytokines Interleukin-8 and Vascular Endothelial Growth Factor in Head and Neck Squamous Cell Carcinoma. Cancer Res 2001; 61:5911-8.
25. Dong G, Lee TL, Yeh NT, Geoghegan J, Waes CV, Chen Z. Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene 2004; 23:6199-208.
26. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research 2009; 15:3740-50.
27. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer. Clinical Cancer Research 2007; 13:4291-9.
28. Zhou X, Yuan Y, Song J, Rothstein ME, Thomas SM, Gubish CT, et al. Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. The Journal of Laryngology & Otology 2009; 123:208-22.
29. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative. Clinical Cancer Research 2007; 13:4964-73.
30. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck. Cancer Res 2005; 65:9953-61.
31. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62.
32. Sorrells DL, Meschonat C, Black D, Li BD. Pattern of Amplification and Overexpression of the Eukaryotic Initiation Factor 4E Gene in Solid Tumor. The Journal of surgical research 1999; 85:37-42.
33. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycinâ, Mediated Increases in Survivin Expression. Clinical Cancer Research 2008; 14:1581-9.
34. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakasaki T, et al. Signal transducers and activators of transcription 3 upregulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncology 2007; 43:785-90.
35. Gabhann FM, Popel AS. Systems Biology of Vascular Endothelial Growth Factors. Microcirculation 2008; 15:715-38.
36. Clasper S, Royston D, Baban D, Cao Y, Ewers S, Butz S, et al. A Novel Gene Expression Profile in Lymphatics Associated with Tumor Growth and Nodal Metastasis. Cancer Res 2008; 68:7293-303.
37. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, et al. Endothelial Cells Enhance Tumor Cell Invasion through a Crosstalk Mediated by CXC Chemokine Signaling. Neoplasia 2008; 10:131-9.
38. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, et al. Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade. Cancer Res 2004; 64:7977-84.
39. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, et al. Cyclin D1 and p16 Alterations in Advanced Premalignant Lesions of the Upper Aerodigestive Tract. Clinical Cancer Research 2001; 7:3127-34.
40. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncology 45:324-34.
41. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009; 21:1255-68.
42. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive Activation of Signal Transducers and Activators of Transcription 3 Correlates with Cyclin D1 Overexpression and May Provide a Novel Prognostic Marker in Head and Neck Squamous Cell Carcinoma. Cancer Res 2002; 62:3351-5.
43. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Nat Acad Sci USA 2004; 101:10602-7.
44. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550-60.
45. Kramer RH, Shen X, Zhou H. Tumor cell invasion and survival in head and neck cancer Cancer and Metastasis Reviews 2005; 24:35-45.
46. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009; 6:266-77.
47. Los M, Roodhart JM, Voest EE. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. Oncologist 2007; 12:443-50.
48. Sachdev J, Jahanzeb M. Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer. Clinical Breast Cancer 2008; 8:402-10.
49. Sen M, Tosca P, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemotherapy and Pharmacology 2009; 63:983-95.
50. Yoo GH, Moon J, LeBlanc M, Lonardo F, Urba S, Kim H, et al. A Phase 2 Trial of Surgery With Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx and Larynx: Report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009; 135:869-74.
51. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated Wild-Type p53 Gene Transfer as a Surgical Adjuvant in Advanced Head and Neck Cancers. Clinical Cancer Research 1999; 5:1715-22.
52. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma. Clinical Cancer Research 2009; 15:5426-34.
53. Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Current Opinion in Pharmacology 2009; 9:389-95.
54. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine and Growth Factor Reviews 2006; 17:141-6.
55. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-25.
56. Zhang W, Matrisian L, Holmbeck K, Vick C, Rosenthal E. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006; 6:52.
57. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences 2009; 106:3794-9.
58. Song N, Huang Y, Shi H, Yuan S, Ding Y, Song X, et al. Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1alpha/CXCR4 Axis. Cancer Res 2009; 69:6057-64.
59. Zhuang Z, Jian P, Longjiang L, Bo H, Hongwei Z. Identification of Oral Cancer Cell-Induced Changes in Gene Expression Profile of Lymphatic Endothelial Cell. Cancer Investigation 2008; 26:1002-7.
60. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006; 354:567-78.
61. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer treatment reviews 2009; 35:354-63.
62. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 2003; 21:1980-7.
63. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25:2178-83.
64. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, et al. Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. J Clin Oncol 2007; 25:3978-84.
65. Eder JP, Heath E, Appleman L, Shapiro G, Wand D, Malburg L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007; 25.
66. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Wolf J, Crino L, et al. A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). J Clin Oncol 2007; 25.
67. Brooks HD, Glisson B, Lu C, Sabichi A, Johnson F, Ginsberg L, et al. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009; 27.
68. Fury MG, Pfister DG. AZD0530 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. www.clinicaltrials.gov 2009.
69. Cruz JJ, Ocana A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18:421-30.
70. Choong N, Kozloff M, Taber D, Hu HS, Wade J, 3rd, Ivy P, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Inves New Drugs 2009.
71. Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 2007; 25.
72. Saura C, Baselga J, Herbst R, Campo JD, Marotti M, Tessier J, et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. J Clin Oncol 2009; 27.
73. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, et al. Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer. J Clin Oncol 2008; 26:1732-41.
74. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. The Lancet Oncology 2009; 10:247-57.
75. Papadimitrakopoulou V, Frank SJ, Blumenschein GR, Chen C, Kane M, Cohen EE, et al. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009; 27.